Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Chang

Hematology & Oncology Newport News, VA Medical Doctor

NPI 1982718078 CMS profile 226014

1051 Loftis Blvd, Suite 100, Newport News, VA 23606

Open in the dashboard

General payments

$141,499

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,034,085 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Chang of Newport News, VA is reported in the CMS Open Payments database as having received $141,499 across 119 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,034,085 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $65,028 40
2024 General $27,448 23
2023 General $34,415 29
2022 General $4,173 8
2021 General $6,771 9
2020 General $3,354 5
2019 General $310 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Chang
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to David Chang were reported at $65,028. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year David Chang Hematology & Oncology median Middle half National median
2019 $310 $529 $121–$2,516 $163
2020 $3,354 $339 $82–$2,213 $114
2021 $6,771 $263 $49–$1,965 $132
2022 $4,173 $416 $103–$2,395 $149
2023 $34,415 $542 $125–$2,646 $160
2024 $27,448 $692 $141–$3,008 $164
2025 $65,028 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $91,457 59 payments
  2. BeOne Medicines USA, Inc. $12,884 7 payments
  3. Exelixis Inc. $7,172 12 payments
  4. Taiho Oncology, Inc. $5,763 3 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $5,198 2 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $4,196 3 payments
  7. G1 Therapeutics, Inc. $3,000 2 payments
  8. BeiGene USA, Inc. $2,186 7 payments
  9. Ipsen Biopharmaceuticals, Inc $1,791 3 payments
  10. Karyopharm Therapeutics Inc. $1,550 1 payment
  11. Other $6,304 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $104,674 33 payments
  2. Consulting Fee $24,506 15 payments
  3. Travel and Lodging $5,611 27 payments
  4. Food and Beverage $3,581 39 payments
  5. Honoraria $3,000 2 payments
  6. Education $127 3 payments
Products named General payments · program years 2019–2025
  1. IMFINZI $43,817 29 payments
  2. TEVIMBRA $12,884 7 payments
  3. Lonsurf $5,763 3 payments
  4. FRUZAQLA $5,198 2 payments
  5. CABOMETYX Oncology $5,192 11 payments
  6. Vitrakvi $3,317 2 payments
  7. COSELA $3,000 2 payments
  8. BRUKINSA $2,186 7 payments
  9. IMJUDO $2,055 1 payment
  10. CABOMETYX Oncology $1,980 1 payment
  11. Other $8,548 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

500

Median for Hematology-Oncology: 604

Drug cost

$1,349,455

Median for Hematology-Oncology: $1,306,514

Branded share of claims

48.4%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 27 $516,057
Fruzaqla Fruquintinib Brand 17 $396,480
Imbruvica Ibrutinib Brand 12 $209,980
Pazopanib Hcl Generic 16 $136,344
Xarelto Rivaroxaban Brand 52 $35,850
Creon Lipase/Protease/Amylase Brand 13 $18,030
Eliquis Apixaban Brand 23 $14,972
Enoxaparin Sodium Generic 14 $7,512
Imatinib Mesylate Generic 14 $7,035
Letrozole Generic 50 $1,717

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 190 billing codes

Paid by Medicare

$2,403,935

Of which drugs: $2,131,524

Medicare patients

795

Average age 75

Services billed

158,282

439 women, 356 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Cancer 47%
Diabetes 34%
Chronic kidney disease 30%
Ischemic heart disease 29%
Depression 23%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 20 2,710 $96,562
Injection, denosumab, 1 mg J0897 Office 30 3,600 $66,022
Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 Office 19 12,254 $28,298
Injection, iron dextran, 50 mg J1750 Office 30 600 $8,055
Injection, aprepitant, 1 mg J0185 Office 14 4,940 $6,780
Injection, azacitidine, 1 mg J9025 Office 15 12,100 $3,538
Injection, fluorouracil, 500 mg J9190 Office 12 679 $1,554
Injection, fosaprepitant, 1 mg J1453 Office 17 9,450 $1,076
Injection, oxaliplatin, 0.5 mg J9263 Office 11 16,560 $907
Injection, palonosetron hcl, 25 mcg J2469 Office 31 1,160 $808

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMFINZI
  • AstraZeneca Pharmaceuticals LP $20,977
$20,977 — —
FRUZAQLA
  • Takeda Pharmaceuticals U.S.A., Inc. $2,760
$2,760 17 —
Vitrakvi
  • Bayer HealthCare Pharmaceuticals Inc. $1,710
$1,710 — —
Lonsurf
  • Taiho Oncology, Inc. $1,560
$1,560 — —
BRUKINSA
  • BeiGene USA, Inc. $134
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record